Please ensure Javascript is enabled for purposes of website accessibility

Why Pfizer, BioNTech, and Moderna Stocks Are Getting a Bump Today

By Keith Speights – Aug 13, 2021 at 11:15AM

Key Points

  • Pfizer, BioNTech, and Moderna stocks rose after the FDA expanded the EUAs for their COVID-19 vaccines to include third booster doses for immunocompromised individuals.
  • The number of individuals covered by the expanded EUAs is relatively small and likely won't impact the companies' sales significantly.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA authorized booster doses for immunocompromised individuals.

What happened

Shares of the leading COVID-19 vaccine makers received a modest bump today. Pfizer (PFE 0.74%) stock was up 1.5% as of 10:38 a.m. EDT on Friday. Shares of the company's partner, BioNTech (BNTX -0.88%), rose 2.2%. Moderna (MRNA -0.23%) stock was also up 2.1%.

There was a common catalyst for these vaccine stocks. The U.S. Food and Drug Administration announced Thursday evening that it had expanded the Emergency Use Authorizations for the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine to include a third booster dose for immunocompromised individuals.

Healthcare professional giving a shot to a person.

Image source: Getty Images.

So what

The FDA specifically mentioned organ transplant recipients as being eligible for booster doses. The agency also said that individuals who are similarly immunocompromised could receive booster shots as well.

While this is good news for Pfizer, BioNTech, and Moderna, it likely won't move the needle very much in terms of sales. Acting FDA commissioner Janet Woodcock used the phrase "small, vulnerable group" to describe the individuals who would qualify for the booster doses. Most Americans won't be affected by the EUA changes.

Now what

Woodcock stated that the agency currently believes that individuals who aren't immunocompromised and are fully vaccinated "are adequately protected and do not need an additional dose of COVID-19 vaccine at this time." However, the FDA continues to review whether or not booster doses will be needed for more people in the U.S. 

Even if the FDA determines that booster doses are appropriate for the larger population, it might not have a huge impact on revenue for Pfizer, BioNTech, and Moderna. The U.S. has already ordered enough doses from the companies to provide booster shots for many Americans.

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41
BioNTech SE Stock Quote
BioNTech SE
BNTX
$154.85 (-0.88%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.